NAPSRx CNPR Exam Practice Test
| 18th Edition (2025)
Section A: Pharmaceutical Industry & Regulation (Q1-25)
Q1: Under the Hatch-Waxman Act, what is granted to the first generic manufacturer to file an
ANDA (Abbreviated New Drug Application) challenging a patent?
A. Tax incentives
B. A user fee waiver
C. 180 days of market exclusivity [CORRECT]
D. Automatic FDA approval
Correct Answer: C
Rationale: The Hatch-Waxman Act provides a 180-day period of marketing exclusivity to the
first generic applicant that challenges a listed patent (Paragraph IV certification). This is a
major incentive for generic competition.
Q2: Which FDA approval pathway is designed to expedite the review of drugs that treat
serious conditions and fill an unmet medical need based on a surrogate endpoint?
A. Fast Track
B. Breakthrough Therapy
C. Accelerated Approval [CORRECT]
D. Priority Review
Correct Answer: C
Rationale: Accelerated Approval allows drugs for serious conditions with unmet needs to be
approved based on a surrogate endpoint (e.g., tumor shrinkage) that is reasonably likely to
predict clinical benefit, rather than waiting for clinical outcomes data. Fast Track facilitates
development; Breakthrough requires preliminary evidence of substantial improvement;
Priority Review shortens review time to 6 months.
,Q3: A pharmaceutical company is required to implement a Risk Evaluation and Mitigation
Strategy (REMS) for a new opioid product. Which component is MANDATORY under FDA
requirements?
A. Patient registry
B. Medication guide and communication plan [CORRECT]
C. Physician certification
D. Patient monitoring database
Correct Answer: B
Rationale: All REMS must include a timetable for submission of assessments and either a
medication guide/patient package insert OR a communication plan to healthcare providers.
Elements to Assure Safe Use (ETASU)—such as physician certification, pharmacies enrolled
in the program, or patient registries—are required only when necessary to mitigate specific
serious risks.
Q4: According to the Prescription Drug Marketing Act (PDMA), which practice is
PROHIBITED?
A. Providing drug samples to licensed physicians for patient use
B. Selling drug samples to wholesale distributors
C. Distributing drug samples through authorized sales representatives [CORRECT]
D. Returning expired samples to the manufacturer for credit
Correct Answer: C
Rationale: The PDMA strictly regulates drug samples to prevent diversion and counterfeit
drugs. Samples must be distributed only to licensed practitioners or hospitals upon written
request; they cannot be sold, traded, or distributed through sales reps as "promotional items."
Samples require detailed tracking and accountability.
Q5: A sales representative offers to buy lunch for an office staff meeting where a brief,
informal discussion about a new drug indication will occur. This is:
A. Always permissible as a "modest meal."
,B. Permissible only if the value is under $100.
C. A potential violation, as the meal should be incidental to a bona fide educational
presentation. [CORRECT]
D. Prohibited under all circumstances.
Correct Answer: C
Rationale: Per the PhRMA Code and federal anti-kickback statutes, meals must be modest in
value and provided in a setting conducive to a bona fide educational presentation. A casual
office lunch with a brief discussion may not meet the "educational presentation" standard,
creating compliance risk.
Q6: The Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) is
primarily used to determine:
A. Drug pricing benchmarks for Medicare reimbursement
B. Therapeutic equivalence ratings between generic and brand-name drugs [CORRECT]
C. Adverse event reporting requirements
D. Clinical trial endpoint standards
Correct Answer: B
Rationale: The FDA Orange Book lists approved prescription and OTC drug products with
therapeutic equivalence evaluations (A-rated codes for bioequivalent products, B-rated for
potential bioequivalence problems). It is the authoritative source for determining whether a
generic can be substituted for a brand-name product.
Q7: During a Phase II clinical trial, the primary objective is to:
A. Assess safety and pharmacokinetics in healthy volunteers
B. Evaluate efficacy and side effects in patients with the target disease [CORRECT]
C. Confirm efficacy in large, diverse populations
D. Monitor long-term safety and rare adverse events
Correct Answer: B
, Rationale: Phase I focuses on safety and PK in healthy volunteers; Phase II evaluates
preliminary efficacy, optimal dosing, and side effects in a small patient population (100-300
subjects); Phase III confirms efficacy in large populations (1,000-3,000+); Phase IV conducts
post-marketing surveillance for rare events and long-term safety.
Q8: A pharmaceutical sales representative learns that a competitor's drug has been recalled
due to contamination. The representative immediately calls physicians to suggest switching
patients to their product. This action is:
A. Appropriate competitive intelligence sharing
B. Permissible if the recall is publicly announced
C. A potential HIPAA violation if patient-specific information is discussed
D. Potentially unethical and may violate company policy on exploiting adverse events
[CORRECT]
Correct Answer: D
Rationale: While discussing publicly available safety information is permissible, proactively
exploiting a competitor's recall to switch patients raises ethical concerns and often violates
company policies regarding appropriate promotion. The focus should remain on the merits of
one's own product, not capitalizing on competitor failures.
Q9: Which of the following is TRUE regarding the IND (Investigational New Drug) application?
A. It is submitted after Phase III trials are completed
B. It requires data from at least two adequate and well-controlled clinical trials
C. It must include preclinical data, manufacturing information, and clinical protocols
[CORRECT]
D. It automatically grants the sponsor the right to market the drug
Correct Answer: C
Rationale: The IND is submitted BEFORE human clinical trials begin. It must contain
preclinical (animal) pharmacology and toxicology data, chemistry/manufacturing information,
and detailed clinical protocols for Phase I studies. Marketing rights are granted only after
NDA/BLA approval.
| 18th Edition (2025)
Section A: Pharmaceutical Industry & Regulation (Q1-25)
Q1: Under the Hatch-Waxman Act, what is granted to the first generic manufacturer to file an
ANDA (Abbreviated New Drug Application) challenging a patent?
A. Tax incentives
B. A user fee waiver
C. 180 days of market exclusivity [CORRECT]
D. Automatic FDA approval
Correct Answer: C
Rationale: The Hatch-Waxman Act provides a 180-day period of marketing exclusivity to the
first generic applicant that challenges a listed patent (Paragraph IV certification). This is a
major incentive for generic competition.
Q2: Which FDA approval pathway is designed to expedite the review of drugs that treat
serious conditions and fill an unmet medical need based on a surrogate endpoint?
A. Fast Track
B. Breakthrough Therapy
C. Accelerated Approval [CORRECT]
D. Priority Review
Correct Answer: C
Rationale: Accelerated Approval allows drugs for serious conditions with unmet needs to be
approved based on a surrogate endpoint (e.g., tumor shrinkage) that is reasonably likely to
predict clinical benefit, rather than waiting for clinical outcomes data. Fast Track facilitates
development; Breakthrough requires preliminary evidence of substantial improvement;
Priority Review shortens review time to 6 months.
,Q3: A pharmaceutical company is required to implement a Risk Evaluation and Mitigation
Strategy (REMS) for a new opioid product. Which component is MANDATORY under FDA
requirements?
A. Patient registry
B. Medication guide and communication plan [CORRECT]
C. Physician certification
D. Patient monitoring database
Correct Answer: B
Rationale: All REMS must include a timetable for submission of assessments and either a
medication guide/patient package insert OR a communication plan to healthcare providers.
Elements to Assure Safe Use (ETASU)—such as physician certification, pharmacies enrolled
in the program, or patient registries—are required only when necessary to mitigate specific
serious risks.
Q4: According to the Prescription Drug Marketing Act (PDMA), which practice is
PROHIBITED?
A. Providing drug samples to licensed physicians for patient use
B. Selling drug samples to wholesale distributors
C. Distributing drug samples through authorized sales representatives [CORRECT]
D. Returning expired samples to the manufacturer for credit
Correct Answer: C
Rationale: The PDMA strictly regulates drug samples to prevent diversion and counterfeit
drugs. Samples must be distributed only to licensed practitioners or hospitals upon written
request; they cannot be sold, traded, or distributed through sales reps as "promotional items."
Samples require detailed tracking and accountability.
Q5: A sales representative offers to buy lunch for an office staff meeting where a brief,
informal discussion about a new drug indication will occur. This is:
A. Always permissible as a "modest meal."
,B. Permissible only if the value is under $100.
C. A potential violation, as the meal should be incidental to a bona fide educational
presentation. [CORRECT]
D. Prohibited under all circumstances.
Correct Answer: C
Rationale: Per the PhRMA Code and federal anti-kickback statutes, meals must be modest in
value and provided in a setting conducive to a bona fide educational presentation. A casual
office lunch with a brief discussion may not meet the "educational presentation" standard,
creating compliance risk.
Q6: The Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) is
primarily used to determine:
A. Drug pricing benchmarks for Medicare reimbursement
B. Therapeutic equivalence ratings between generic and brand-name drugs [CORRECT]
C. Adverse event reporting requirements
D. Clinical trial endpoint standards
Correct Answer: B
Rationale: The FDA Orange Book lists approved prescription and OTC drug products with
therapeutic equivalence evaluations (A-rated codes for bioequivalent products, B-rated for
potential bioequivalence problems). It is the authoritative source for determining whether a
generic can be substituted for a brand-name product.
Q7: During a Phase II clinical trial, the primary objective is to:
A. Assess safety and pharmacokinetics in healthy volunteers
B. Evaluate efficacy and side effects in patients with the target disease [CORRECT]
C. Confirm efficacy in large, diverse populations
D. Monitor long-term safety and rare adverse events
Correct Answer: B
, Rationale: Phase I focuses on safety and PK in healthy volunteers; Phase II evaluates
preliminary efficacy, optimal dosing, and side effects in a small patient population (100-300
subjects); Phase III confirms efficacy in large populations (1,000-3,000+); Phase IV conducts
post-marketing surveillance for rare events and long-term safety.
Q8: A pharmaceutical sales representative learns that a competitor's drug has been recalled
due to contamination. The representative immediately calls physicians to suggest switching
patients to their product. This action is:
A. Appropriate competitive intelligence sharing
B. Permissible if the recall is publicly announced
C. A potential HIPAA violation if patient-specific information is discussed
D. Potentially unethical and may violate company policy on exploiting adverse events
[CORRECT]
Correct Answer: D
Rationale: While discussing publicly available safety information is permissible, proactively
exploiting a competitor's recall to switch patients raises ethical concerns and often violates
company policies regarding appropriate promotion. The focus should remain on the merits of
one's own product, not capitalizing on competitor failures.
Q9: Which of the following is TRUE regarding the IND (Investigational New Drug) application?
A. It is submitted after Phase III trials are completed
B. It requires data from at least two adequate and well-controlled clinical trials
C. It must include preclinical data, manufacturing information, and clinical protocols
[CORRECT]
D. It automatically grants the sponsor the right to market the drug
Correct Answer: C
Rationale: The IND is submitted BEFORE human clinical trials begin. It must contain
preclinical (animal) pharmacology and toxicology data, chemistry/manufacturing information,
and detailed clinical protocols for Phase I studies. Marketing rights are granted only after
NDA/BLA approval.
